New glioblastoma treatment with added medication after chemoradiation
Treatments studied
Part of Cancer clinical trials.
This Phase 1/2 trial tests an “add-on” medicine (adjuvant therapy) for people newly diagnosed with glioblastoma (GBM) after standard chemoradiation. It aims to see how well the treatment works and how safe it is for patients following initial therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You were newly diagnosed with glioblastoma (GBM).
- Your main initial treatment included chemoradiation (chemotherapy plus radiation).
- You have blood test counts high enough (hemoglobin, white blood cells, neutrophils, lymphocytes, and platelets).
- Your kidney and liver blood tests are within limits, and your overall strength is good (Karnofsky score 70 or higher).
- You are not taking other alternative therapies, are not pregnant, and are not breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests whether adding an immune therapy called retifanlimab to radiation (and a chemotherapy medicine called temozolomide, in some parts of the study) is safe and helpful for newly diagnosed glioblastoma patients after surgery with carmustine wafers. It aims to see how well this combination controls the cancer and what side effects are expected.
This Phase 1 trial studies whether adding eflornithine to temozolomide (chemotherapy) is safe and potentially helpful for people with newly diagnosed glioblastoma or certain astrocytomas after radiation. It aims to find a workable treatment approach by closely monitoring side effects and early tumor responses.
This Phase 1 study tests the safety and early effectiveness of BEY1107 combined with temozolomide in adults whose glioblastoma has come back or kept growing after standard treatment. If you qualify, you may be able to receive this combination while the researchers closely monitor side effects and tumor response.
This Phase 2 study tests whether adding metformin to standard radiation and temozolomide (chemo) can improve outcomes for people with newly diagnosed glioblastoma of a specific metabolic subtype. It aims to see if this combination is safer and more effective than standard treatment alone.
This trial tests whether adding a drug called mycophenolate mofetil (MMF) to standard treatment for newly diagnosed glioblastoma (a serious brain cancer) can help patients live longer and better. You'd receive the usual treatment—radiation and chemotherapy—plus the new drug.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
Hear when a new Glioblastoma Multiforme trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.